

**AMENDMENTS TO THE CLAIMS**

1. (Currently Amended) A peptide-lipid complex in an aqueous solution, ~~characterised in that wherein~~ said lipid is a bilayer-forming galactolipid material and that the weight ratio between the peptide and the galactolipid material is 1:5 – 1:50, with the proviso that the peptide is not LL-37.

2. (Currently Amended) The ~~complex~~ method according to ~~claim 1~~ claim 22, wherein the weight ratio between the peptide and the galactolipid material is 1:10 - 1:50.

3. (Currently Amended) The ~~complex~~ method according to ~~claim 1 or 2~~ claim 22, wherein said peptide is a charged and amphiphilic peptide having a molecular weight below 30 kDa.

4. (Currently Amended) The ~~complex~~ method according to ~~any of claims 1-3~~ claim 22, wherein the peptide has at least four positively charged amino acids.

5. (Currently Amended) The ~~complex~~ method according to ~~any of claims 1-4~~ claim 22, wherein the peptide is in the form of a pharmaceutically acceptable salt.

6. (Currently Amended) The ~~complex~~ method according to ~~any of claims 1-5~~ claim 22, wherein the galactolipid material is a polar lipid mixture rich in digalactosyldiacylglycerols.

7. (Currently Amended) The ~~complex~~ method according to ~~any of claims 1-6~~ claim 22, wherein the galactolipid material is CPL-Galactolipid.

8. (Currently Amended) The ~~complex~~ method according to ~~any of claims 1-7~~ claim 22, wherein the peptide is an apolipoprotein or an apolipoprotein analogue.

9. (Currently Amended) The ~~complex~~ method according to ~~any of claims 1-7~~ claim 22, wherein the peptide is selected from the group consisting of insulin, glucagon, erythropoietin, darbepoietin, streptokinase, somatropin, desmopressin, oxytocin, gonadorelin, nafarelin, octreotid, lanreotid, ganirelix, cetrorelix, teriparalid, and salmon calcitonin.

10. (Currently Amended) The ~~complex~~ method according to ~~any of claims 1-7~~ claim 22, wherein the peptide is selected from the group consisting of magainin 2, cecropin, and histatin.

11. (Currently Amended) The ~~complex~~ method according to ~~any of claims 1-7~~ claim 22, wherein said peptide is a cationic antimicrobial peptide having a molecular weight of 2.5 - 5 kDa.

12. (Currently Amended) The ~~complex~~ method according to ~~any of claims 1-7 and 11~~ claim 22, having a peptide:galactolipid weight ratio of 1:10 - 1:27.

13. (Currently Amended) The ~~complex~~ method according to ~~any of claims 1-7, 11 and 12~~ claim 22, wherein the peptide is selected from the group consisting of LL-25, LL-26, LL-27, LL-28, LL-29, LL-30, LL-31, LL-32, LL-33, LL-34, LL-35, LL-36, and LL-38.

14. (Currently Amended) The ~~complex~~ method according to ~~any of claims 1-7, and 11-13~~ claim 22, comprising the peptide LL-25 and a galactolipid material.

15. (Currently Amended) A colloidal solution of a ~~complex~~ the medicament composition according to ~~any of claims 1-14~~ claim 19, wherein the mean size of said complexes of said ingredient (a) is below 100 nm.

16. (Original) A colloidal solution of a complex between LL-37 and a bilayer-forming galactolipid material, wherein the mean size of said complexes is below 100 nm.

17. – 18. (Cancelled)

19. (Currently Amended) ~~Use of a colloidal solution of a complex according to any of claims 1-16 for the manufacture of a medicament~~ A medicament composition comprising

(a) a peptide-lipid complex in an aqueous solution, wherein said lipid is a bilayer-forming galactolipid material and that the weight ratio between the peptide and the galactolipid material is 1:5 – 1:50, with the proviso that the peptide is not LL-37; or

(b) a complex between LL-37 and a bilayer-forming galactolipid material, wherein the mean size of said complexes is below 100 nm.

20. (Currently Amended) ~~Use of a colloidal solution of a complex according to claim 15 or 16 for the manufacture of a medicament for treatment of infections, wound healing or other diseases with a deficiency in antimicrobial activity~~ A method of treating infections, wound healing or other diseases with a deficiency in antimicrobial activity comprising:

treating a patient in need thereof with a composition according to claim 19.

21. (Cancelled)

22. (New) The method of claim 20, which comprises treating a patient in need thereof with said ingredient (a).

23. (New) The method of claim 20, which comprises treating a patient in need thereof with said ingredient (b).